title: Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer.
abstract: Interviewed by Ellen Clarke, Commissioning Editor, Future Science Group. Robert Coffin is co-founder and CEO of Replimune. Previously he was Founder and CTO of BioVex Inc, a spin out from his research group at University College London in 1999. He was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal Phase 3 studies in melanoma and head and neck cancer. BioVex was acquired by Amgen in 2011 where he was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in USA. He was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.
authors.affiliation: Replimune Ltd, The Oxford Science Park Magdalen Centre, Robinson Avenue, Oxford OX4 4GA.
authors.forename: Robert
authors.initials: R
authors.lastname: Coffin
mesh_terms: D000818:Animals; D049674:History, 21st Century; D006801:Humans; D008545:Melanoma / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000266:history / Q000379:methods*; D050504:Oncolytic Viruses; D011173:Portraits as Topic
keywords: Imlygic; T-VEC; oncolytic immunotherapy